Bolt Biotherapeutics has announced the acquisition of fellow USA-based Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies ...
A San Diego-based biotech company focused on advancing cell, gene, and mRNA-based therapies. Artis emerged from stealth in April 2025 with the acquisition of Landmark Bio, a prominent cell and gene ...
A US biotechnology company targeting severe autoimmune diseases, Priovant Therapeutics won FDA approval in August 2026 for Lisraya (brepocitinib), the first oral drug indicated for dermatomyositis in ...
A clinical-stage biotech developing bispecific antibody therapies that simultaneously block tumor growth and reduce immune suppression. Its proprietary platforms, TRAILBody and TIE‑ADC, are being ...
The European Commission has approved an indication extension for Johnson & Johnson's Tecvayli (teclistamab) as monotherapy ...
US biotech Star Therapeutics, which is focused on the discovery and development of life-changing therapies for diseases with ...
Emergency Task Force (ETF) and the African Medicines Agency (AMA) have published a joint position paper to support the timely ...
Germany-headquartered CNS drug specialist Neuraxpharm Group today announced the presentation of new scientific data on Briumvi (ublituximab) at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to ...
US pharma major Bristol Myers Squibb and SystImmune, the US biotech, said the Phase III PANKU-Breast01 trial of izalontamab ...
A Florida-based, UK-run biotech whose cord-derived cell therapy Ebstrocel is heading for a UK filing in the rare skin disease ...
Danish drugmaker Novo (NOV: N) and US pharma major Eli Lilly (NYSE: LLY) are competing across a widening range of obesity ...
Shares in UCB, the Belgian biopharma company, closed 21.6% higher at 259.10 euros on Thursday after it raised its 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results